Aerovate Therapeutics, Inc. (AVTE)
| Market Cap | 76.81M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -84.61M |
| Shares Out | 28.87M |
| EPS (ttm) | -2.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,315 |
| Open | 2.610 |
| Previous Close | 2.610 |
| Day's Range | 2.585 - 2.690 |
| 52-Week Range | 1.250 - 32.420 |
| Beta | 1.00 |
| Analysts | Hold |
| Price Target | 11.75 (+341.73%) |
| Earnings Date | Nov 12, 2024 |
About AVTE
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AVTE stock is "Hold." The 12-month stock price forecast is $11.75, which is an increase of 341.73% from the latest price.
News
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Aerovate Thera...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders
NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...
Aerovate Therapeutics to Explore Strategic Alternatives
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled ...
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws....
Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses AV-101 did not meet the primary endpoint of change in pulmonary vascular resistan...
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The g...
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHC...
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives ...
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients...
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients...
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerov...
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
WALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...
Aerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAH
Aerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAH
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives ...
Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market
AVTE reported Q4 2023 earnings in line with expectations and has enough cash runway until H2 2025. AV-101, AVTE's lead asset, is on track with patient enrollment in phase 2b PAH trial, and top-line Ph...
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
WALTHAM, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...
Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy
Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-101's Phase 2b PAH data is expected in 4Q 2023 or 1Q 2024, which we believe will be positive.
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...